Literature DB >> 17664316

Orally administered combined regimens for treatment of Mycobacterium ulcerans infection in mice.

Baohong Ji1, Aurélie Chauffour, Jérôme Robert, Sébastien Lefrançois, Vincent Jarlier.   

Abstract

Eight weeks of treatment with rifampin-streptomycin sterilizes Mycobacterium ulcerans infection in mice. Because the bactericidal activity against M. ulcerans of the combination rifampin-moxifloxacin, rifampin-clarithromycin, or moxifloxacin-clarithromycin was similar to that of rifampin-streptomycin, these combinations might be considered as alternative, orally administered combined regimens for treatment of Buruli ulcer in humans.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17664316      PMCID： PMC2043285          DOI： 10.1128/AAC.00730-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  5 in total

1.  In vitro and in vivo activities of rifampin, streptomycin, amikacin, moxifloxacin, R207910, linezolid, and PA-824 against Mycobacterium ulcerans.

Authors:  Baohong Ji; Sébastien Lefrançois; Jerome Robert; Aurélie Chauffour; Chantal Truffot; Vincent Jarlier
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

2.  Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans.

Authors:  S Etuaful; B Carbonnelle; J Grosset; S Lucas; C Horsfield; R Phillips; M Evans; D Ofori-Adjei; E Klustse; J Owusu-Boateng; G K Amedofu; P Awuah; E Ampadu; G Amofah; K Asiedu; M Wansbrough-Jones
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

3.  Curing Mycobacterium ulcerans infection in mice with a combination of rifampin-streptomycin or rifampin-amikacin.

Authors:  Sébastien Lefrançois; Jérôme Robert; Aurélie Chauffour; Baohong Ji; Vincent Jarlier
Journal:  Antimicrob Agents Chemother       Date:  2006-11-13       Impact factor: 5.191

4.  Promising clinical efficacy of streptomycin-rifampin combination for treatment of buruli ulcer (Mycobacterium ulcerans disease).

Authors:  Annick Chauty; Marie-Françoise Ardant; Ambroise Adeye; Hélène Euverte; Augustin Guédénon; Christian Johnson; Jacques Aubry; Eric Nuermberger; Jacques Grosset
Journal:  Antimicrob Agents Chemother       Date:  2007-05-25       Impact factor: 5.191

5.  Isolation of three Mycobacterium ulcerans strains resistant to rifampin after experimental chemotherapy of mice.

Authors:  Laurent Marsollier; Nadine Honoré; Pierre Legras; Anne Lise Manceau; Henri Kouakou; Bernard Carbonnelle; Stewart T Cole
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191
  5 in total
  23 in total

1.  Chemotherapy-associated changes of histopathological features of Mycobacterium ulcerans lesions in a Buruli ulcer mouse model.

Authors:  Marie-Thérèse Ruf; Daniela Schütte; Aurélie Chauffour; Vincent Jarlier; Baohong Ji; Gerd Pluschke
Journal:  Antimicrob Agents Chemother       Date:  2011-12-05       Impact factor: 5.191

Review 2.  Treating Mycobacterium ulcerans disease (Buruli ulcer): from surgery to antibiotics, is the pill mightier than the knife?

Authors:  Paul J Converse; Eric L Nuermberger; Deepak V Almeida; Jacques H Grosset
Journal:  Future Microbiol       Date:  2011-10       Impact factor: 3.165

Review 3.  Pathogenesis of skin ulcers: lessons from the Mycobacterium ulcerans and Leishmania spp. pathogens.

Authors:  Laure Guenin-Macé; Reid Oldenburg; Fabrice Chrétien; Caroline Demangel
Journal:  Cell Mol Life Sci       Date:  2014-01-21       Impact factor: 9.261

Review 4.  Buruli Ulcer, a Prototype for Ecosystem-Related Infection, Caused by Mycobacterium ulcerans.

Authors:  Dezemon Zingue; Amar Bouam; Roger B D Tian; Michel Drancourt
Journal:  Clin Microbiol Rev       Date:  2017-12-13       Impact factor: 26.132

5.  Pharmacokinetics of rifampin and clarithromycin in patients treated for Mycobacterium ulcerans infection.

Authors:  J W C Alffenaar; W A Nienhuis; F de Velde; A T Zuur; A M A Wessels; D Almeida; J Grosset; O Adjei; D R A Uges; T S van der Werf
Journal:  Antimicrob Agents Chemother       Date:  2010-06-28       Impact factor: 5.191

6.  Comparative Study of Activities of a Diverse Set of Antimycobacterial Agents against Mycobacterium tuberculosis and Mycobacterium ulcerans.

Authors:  Nicole Scherr; Gerd Pluschke; Manoranjan Panda
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

7.  Impacts of dosing frequency of the combination rifampin-streptomycin on its bactericidal and sterilizing activities against Mycobacterium ulcerans in mice.

Authors:  Baohong Ji; Aurélie Chauffour; Alexandra Aubry; Jérome Robert; Murad Ibrahim; Vincent Jarlier
Journal:  Antimicrob Agents Chemother       Date:  2009-04-13       Impact factor: 5.191

8.  Bactericidal and sterilizing activities of several orally administered combined regimens against Mycobacterium ulcerans in mice.

Authors:  Baohong Ji; Aurélie Chauffour; Jérome Robert; Vincent Jarlier
Journal:  Antimicrob Agents Chemother       Date:  2008-04-07       Impact factor: 5.191

9.  Clinical and bacteriological efficacy of rifampin-streptomycin combination for two weeks followed by rifampin and clarithromycin for six weeks for treatment of Mycobacterium ulcerans disease.

Authors:  Richard O Phillips; Fred S Sarfo; Mohammed K Abass; Justice Abotsi; Tuah Wilson; Mark Forson; Yaw A Amoako; William Thompson; Kingsley Asiedu; Mark Wansbrough-Jones
Journal:  Antimicrob Agents Chemother       Date:  2013-12-09       Impact factor: 5.191

10.  Bactericidal activity does not predict sterilizing activity: the case of rifapentine in the murine model of Mycobacterium ulcerans disease.

Authors:  Deepak V Almeida; Paul J Converse; Si-Yang Li; Sandeep Tyagi; Eric L Nuermberger; Jacques H Grosset
Journal:  PLoS Negl Trop Dis       Date:  2013-02-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.